DQP 1105

Pricing Availability   Qty
Description: GluN2C/GluN2D-selective NMDA antagonist
Chemical Name: 5-(4-Bromophenyl)-3-(1,2-dihydro-6-methyl-2-oxo-4-phenyl-3-quinolinyl)-4,5-dihydro-γ-oxo-1H-pyrazole-1-butanoic acid
Purity: ≥97% (HPLC)
Datasheet
Citations (2)
Reviews
Literature (5)

Biological Activity for DQP 1105

DQP 1105 is a noncompetitive NMDA receptor antagonist; displays over 50-fold selectivity for GluN2D- and GluN2C-containing receptors over GluN2B-, GluK2-, GluA1- and GluN2A-containing receptors (IC50 values are 2.7, 8.5, 121, 153, 198 and 206 μM, respectively). Reduces frequency of channel opening.

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

Compound Libraries for DQP 1105

DQP 1105 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for DQP 1105

M. Wt 558.42
Formula C29H24BrN3O4
Storage Store at -20°C
Purity ≥97% (HPLC)
CAS Number 380560-89-4
PubChem ID 2723792
InChI Key JIQFFACVQXXHMY-YDALLXLXSA-N
Smiles O=C2C(C4=NN(C(CCC(O)=O)=O)C(C5=CC=C(Br)C=C5)C4)=C(C3=CC=CC=C3)C1=CC(C)=CC=C1N2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for DQP 1105

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 55.84 100

Preparing Stock Solutions for DQP 1105

The following data is based on the product molecular weight 558.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.79 mL 8.95 mL 17.91 mL
5 mM 0.36 mL 1.79 mL 3.58 mL
10 mM 0.18 mL 0.9 mL 1.79 mL
50 mM 0.04 mL 0.18 mL 0.36 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for DQP 1105

Certificate of Analysis / Product Datasheet
Select another batch:

References for DQP 1105

References are publications that support the biological activity of the product.

Acker et al (2011) Mechanism for noncompetitive inhibition by novel GluN2C/D N-MthD.-aspartate receptor subunit-selective modulators. Mol.Pharmacol. 80 782 PMID: 21807990


If you know of a relevant reference for DQP 1105, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: DQP 1105, DQP 1105 supplier, DQP1105, supplier, NMDAD, Glu2NC, antagonists, selective, noncompetitive, inhibitors, inhibits, NMDA, Receptors, 4491, Tocris Bioscience

2 Citations for DQP 1105

Citations are publications that use Tocris products. Selected citations for DQP 1105 include:

Brancaccio et al (2017) Astrocytes Control Circadian Timekeeping in the Suprachiasmatic Nucleus via Glutamatergic Signaling. Neuron 93 1420 PMID: 28285822

Lozovaya et al (2014) Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model. Nat Commun 5 4563 PMID: 25081057


Do you know of a great paper that uses DQP 1105 from Tocris? Please let us know.

Reviews for DQP 1105

There are currently no reviews for this product. Be the first to review DQP 1105 and earn rewards!

Have you used DQP 1105?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.